Tag: Anticoagulants

Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban

Rates of clinically relevant bleeding similar between groups receiving edoxaban or standard-of-care anticoagulation

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Stroke patients with normal, but not those with impaired, renal function have greater benefit with ticagrelor-aspirin than clopidogrel-aspirin

Risks for ischemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban for atrial fibrillation and valvular heart disease

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Quality improvement effort tied to decrease in major bleeding without increase in thrombotic events

Two strong recommendations developed against use of heparin bridging in a-fib, and for continuation of VKA in patients getting pacemaker/ICD

However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy

Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants